Company intelligence / Profile preview

Empirical Health

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Empirical Health offers AI-enhanced, clinician-reviewed personalized health and prevention plans based on wearable and lab biomarker data, with a focus on heart disease risk reduction and chronic condition management. Core product Empirical Health Radar launched March 2025 combines 40+ biomarkers for comprehensive user health scoring and actionable plans; validated metrics such as ApoB and VO2 Max are tracked for risk modification[1][2][3][4].

Therapeutic areas: NephrologyCardiovascularPulmonologyNeurologyPsychiatry
Modalities: Digital healthDeviceDiagnosticsNon-pharmacological therapy
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Empirical Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Empirical Health.

Explore the full profile